Lymphoma

The manufacturer of the novel CAR-T cell therapy announced it terminated an early-phase trial investigating the treatment’s efficacy after there was a lack of benefit in patients with relapsed or refractory T-cell lymphoma, a type of blood cancer.

The FDA approval of Breyanzi, a novel CAR-T cell therapy, provides many patients with lymphoma a new treatment option that can be used earlier in the course of their disease, according to an expert.

The FDA approval of Breyanzi, a CAR-T cell therapy, offers patients with relapsed/refractory lymphoma the opportunity for long-term remission, and hope for a cure, one expert said.

From Robin Roberts’ personal message about her partner, Amber Laign’s cancer, to a dancing group inspired by an “America’s Got Talent” contestant who died of cancer, here’s what is happening in the cancer space this week.

Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.

Losing my hair due to cancer treatment was mentally and physically painful, but I learned a few tips and tricks along the way.

When you put your feelings out there in cancer support groups — be it in-person or virtual — you’re opening your ideas up to others’ interpretation, and some might not like what you have to say.

Watching my sister undergo cancer treatment made me want to become a nurse, though after she was re-diagnosed, I’ve had to step away from that career path.

I can’t stand the “battle language” of cancer, including terms like “cancer warrior” and “losing the battle” with the disease.

From “Leave It to Beaver” actor Tony Dow revealing his cancer diagnosis to a woman faking a cancer diagnosis to collect $100,000 in donations and a European soccer star finishing treatment, here’s what’s happening in the cancer space this week.

After my sister was re-diagnosed with stage 4 cancer, I was reminded to find laughter in every day because nobody knows what tomorrow holds.

The majority of patients with relapsed/refractory large B-cell lymphoma were alive between four and five years after being treated with axi-cel.

A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.

Findings from an early-phase clinical trial show that treatment with epcoritamab led to a 63.1% response rate in patients with pretreated large B-cell lymphoma.

After going public with my cancer diagnosis, I was met with an onslaught of “grief tourists” who may not have been interested in the harsh realities of cancer.

After surviving cancer, I’ve developed complex post-traumatic stress disorder, which comes with feelings of insecurity and anger.

The plan is to assess the safety and efficacy of the genetically engineered cell therapy alongside high-dose chemotherapy and blood stem cell transplantation in approximately 150 patients with lymphoma.

The FDA’s decision to approve Yescarta in patients with large B-cell lymphoma that has failed to respond to first-line treatment is based on data that showed that the use of the CAR-T cell therapy resulted in a significant increase in patients who were alive at two years compared with the standard-of-care second-line treatment.

My survivor friends and I share the insensitive comments we have received about our cancer diagnosis.

After seeing my brother go through extraordinary pain because of lymphoma and then surviving breast cancer myself, I always pushed through the pain — even when I shouldn’t have.

There are now more drugs than ever to treat and prevent graft-versus-host disease in patients with blood cancer who receive a stem cell transplant.

The Food and Drug Administration will review data on Breyanzi (lisocabtagene maraleucel) — a CAR-T cell therapy — for use in the second-line setting for patients with relapsed or refractory large B-cell lymphoma to determine if the indication will be granted approval.

Supportive care should be implemented promptly after patients receive CAR-T cell therapy, but as one expert notes, patients with cancer are often referred for this care too late.

A survivor of multiple cancers explains how “visits” from deceased friends and loved ones made her feel safe before undergoing treatments.

A woman explains how she grapples with the acceptance that her sister may never enter remission from cancer.

Recent study results showed that the use of a remote monitoring device worn on the upper arm may help patients with blood cancers seek assistance for serious complications while receiving intensive treatments.

CAR-T cell therapy with Yescarta in patients with relapsed/refractory large B-cell lymphoma had improved responses to treatment and survival in the second-line setting, which may help save more lives than standard care, an expert said.

The National Comprehensive Cancer Network now recommends prophylactic monoclonal antibodies for immunosuppressed individuals, such as certain patients with cancer.

A phase 2 trial was recently launched to examine the safety and efficacy of oral inhibitor VK-2019 in patients with advanced Epstein-Barr Virus-positive nasopharyngeal carcinoma, a rare type of head and neck cancer, and lymphoma.

2021 was full of research advancements and FDA drug approvals that continue to improve cancer care for patients with a variety of malignancies.